Table 1.
The concentrations of raloxifene species (M1, M2, Ral) and the measured changes in bone mineral density (BMD) after 12 months' treatment in the observed UGT1A1 genotype groups
| UGT1A1 genotype | Genotype frequency (%) | c(M1) (nmol l−1) | c(M2) (nmol l−1) | c(Ral) (nmol l−1) | Δ BMD HIP (%) | Δ BMD FN (%) | Δ BMD L1–L4 (%) |
|---|---|---|---|---|---|---|---|
| *1/*1 | 35 | 48 ± 11 | 203 ± 47 | 3.8 ± 0.8 | −0.6 ± 1.0 | 2.5 ± 1.0 | 2.2 ± 0.8 |
| (25, 73) | (47, 103) | (2.0, 5.5) | (−2.6, 1.4) | (0.3, 4.6) | (0.4, 4.0) | ||
| *1/*28 | 46 | 58 ± 12 | 274 ± 54 | 2.9 ± 0.5 | 1.1 ± 2.4 | 0.9 ± 1.3 | 1.9 ± 1.0 |
| (33, 83) | (54, 161) | (1.9, 4.0) | (−3.8, 6.0) | (−1.7, 3.4) | (−0.3, 4.0) | ||
| *28/*28 | 19 | 102 ± 24 | 457 ± 94 | 4.3 ± 1.1 | 4.4 ± 2.4 | 1.8 ± 1.1 | 2.4 ± 1.3 |
| (48, 155) | (243, 670) | (1.8, 6.9) | (−0.9, 9.6) | (−0.7, 4.2) | (−0.6, 5.3) |
The values of ΔBMD are presented as arithmetic means ± standard errors and the numbers in parentheses represent 95% confidence intervals.